• Structural Growth Expected with 2027 Inclusion of Diabetic Foot Ulcer (DFU) in National Health Insurance

ROKIT Healthcare has developed an organ regeneration platform that combines AI and 3D bioprinting to recreate damaged tissues and organs using a patient’s own (autologous) tissue. Since completing the platform's development in 2022, the company has been expanding its applications from skin to cartilage and kidneys. In domestic pilot clinical trials for Diabetic Foot Ulcer (DFU) treatment, the company recorded an 80% (8/10 patients) complete healing rate within 16 weeks, confirming superior results compared to the 50% (3/6 patients) seen in Standard of Care (SOC). Currently, the treatment is available as a non-reimbursable service at designated hospitals. If clinical data from approximately 100 patients is secured, it is expected to transition to national health insurance coverage by the second half of 2027. Upon coverage, the patient's out-of-pocket cost is projected to drop to approximately 240,000 KRW—about one-tenth of the current cost. This drastic improvement in treatment accessibility is expected to drive structural growth in domestic DFU revenue.

• Laying the Foundation for Growth through Indication Expansion in the U.S.

On a consolidated basis, the company’s 2025 revenue reached 26.2 billion KRW (+100.2% YoY), successfully achieving a turnaround with an operating profit of 600 million KRW. Notably, 43.9% of total revenue was generated overseas, supported by a global network established through sales agreements with 46 countries. In the U.S. market, the company entered the DFU treatment space through Ties Medical and is currently anticipating the acquisition of CPT (Current Procedural Terminology) codes. Furthermore, in February 2026, the company signed a Mutual Confidentiality Agreement (MCA) with Northwell Health for strategic cooperation in skin cancer regeneration technology, paving the way for entry into the skin cancer market. These developments are expected to drive platform unit price increases and market expansion through the broadening of indications in the U.S.

• 2026 Milestones: Clinical Data for Kidney and Cartilage Regeneration

The revenue growth trend is expected to persist through 2026. However, as clinical trials for kidney and cartilage regeneration move into full swing, operating profit volatility may increase due to rising R&D and clinical expenses. - Kidney Regeneration: Recruitment for a domestic pilot trial (10 participants) has been completed, with partial results expected to be released starting in June 2026. - Cartilage Regeneration: Domestic clinical trials are currently underway, and an expansion into clinical trials in the Middle East through partner companies is also anticipated.